Status: Not yet recruiting
MLC1501 Study Assessing Efficacy in STROke Recovery
This is a multi-center, randomized, double-blind, placebo-controlled, dose-response study of MLC1501 in patients with stroke. Eligible participants will be randomized in a 1:1:1 ratio to orally receive MLC1501 low-dose twice a day, MLC1501 high-dose twice a day, or matching placebo for 24 weeks.
Participants needed: 540
Trial details
Phase: Phase 2, Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Moleac Pte Ltd.Updated: Mar 16, 2023
Eligibility criteria
Male or female. [+5]
Pre-stroke modified Rankin score of >1. [+8]